Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Diagnostic Approach to Elevated Lactoferrin with Clear Endoscopy

Understanding Elevated Lactoferrin

  • Lactoferrin has 83% sensitivity and 75% specificity for detecting moderate to severe endoscopic inflammation in inflammatory bowel disease (IBD), meaning approximately 25% of elevated results may not reflect true endoscopic inflammation, which appears consistent with negative endoscopic findings 2, 4
  • The American Gastroenterological Association (AGA) recommends interpreting lactoferrin levels in context, considering factors such as symptoms, endoscopic findings, and biomarker results 1, 2

Diagnostic Considerations

  • Capsule endoscopy, colonoscopy, and upper endoscopy can miss subtle mucosal inflammation, particularly in the small bowel or when inflammation is microscopic rather than macroscopic 1
  • Fecal biomarkers, such as lactoferrin, can detect inflammation at a molecular level before it becomes visually apparent on endoscopy, with a diagnostic threshold of 7.25 μg/g used to detect intestinal inflammation 1, 3

Management Strategy

  • The AGA recommends repeat fecal lactoferrin measurement in 3-6 months rather than proceeding to empiric treatment or repeat endoscopy for patients with mild or absent symptoms, elevated biomarkers, and no endoscopic confirmation of inflammation 1, 2
  • If lactoferrin remains elevated on repeat testing, proceed with repeat endoscopic assessment, potentially with biopsies from previously normal-appearing areas, to establish whether lactoferrin correlates with the specific disease pattern 1, 2

Monitoring and Treatment

  • If repeat lactoferrin normalizes (<7.25 μg/g), continue monitoring symptoms, and no further biomarker testing is needed unless symptoms develop 1, 2
  • If repeat lactoferrin remains elevated and endoscopy confirms inflammation, treatment should be adjusted based on endoscopic findings, and monitor both lactoferrin and fecal calprotectin to determine which correlates better with disease activity 2, 6